Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • crawfordlong1815 crawfordlong1815 Jan 13, 2011 3:36 PM Flag

    $8 target makes incredible assumptions.

    You are correct in that biotechs lose money due to R and D and no income. However, once the product is approved the burn rate will substantially decrease. If you look at my assumptions you will notice a net margin of 50% so I have accounted to expenses related to marketing, supporting and managing product sales. Insurance companies are very sharp when it comes to approving a treatment or not. They will see how much their current cost of therapy is for a patient, for refract gout it can be very high.

 
SVNTQ
0.00(0.00%)